In this episode, Jona Tanguay, MMSc, PA-C, AAHIVS discusses considerations to review with patients to empower them to make their own informed choices in PrEP selection, including:
Leveraging PrEP options with unique dosing schedules and/or routes such as long-acting cabotegravir and on-demand 2-1-1 FTC/TDF
Differences in adverse effect profiles between 4 PrEP options
Potential for HIV resistance
Requirements for compliance and monitoring
Evidence in populations with various acquisition behaviors
Drug interaction implications
Faculty:
Jona Tanguay, MMSc, PA-C, AAHIVS
Health Care Provider and HIV Specialist
Whitman-Walker Health
Vice President for Education, GLMA: Health Professionals Advancing LGBTQ Equality
Clinical Instructor, Yale University School of Nursing
Washington, DC
Link to full program: https://bit.ly/41WF54o
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Podden och tillhörande omslagsbild på den här sidan tillhör
Practicing Clinicians Exchange. Innehållet i podden är skapat av Practicing Clinicians Exchange och inte av,
eller tillsammans med, Poddtoppen.